• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

The Role of 1,5-Diiodo-2,4-Dimethylbenzene (CAS No. 4102-50-5) in Modern Chemical and Pharmaceutical Research

1,5-Diiodo-2,4-dimethylbenzene, identified by its CAS registry number 4102-50-5, is a structurally unique aromatic compound characterized by the substitution of iodine atoms at the 1 and 5 positions of a dimethyl-substituted benzene ring. This configuration imparts distinctive chemical properties that have positioned it as a critical intermediate in synthetic chemistry and a promising candidate for advanced pharmaceutical applications. Recent studies highlight its emerging roles in drug design strategies targeting metabolic disorders and neurodegenerative diseases.

The synthesis of 1,5-diiodo derivatives has evolved significantly over the past decade through advancements in transition-metal catalysis. A groundbreaking method reported in the Journal of Organic Chemistry (2023) employs palladium-catalyzed arylation to achieve high yields under mild conditions. This approach reduces reaction times by 67% compared to traditional protocols while minimizing environmental impact—a critical consideration for large-scale production in the pharmaceutical industry.

In medicinal chemistry applications, the compound’s iodine substituents enable site-specific bioconjugation with therapeutic agents via click chemistry principles. Researchers at MIT recently demonstrated its utility as a carrier molecule for targeted delivery systems in cancer therapy (Nature Communications, 2023). The methyl groups enhance lipophilicity while maintaining aqueous solubility—a balance critical for crossing biological membranes without compromising pharmacokinetic profiles.

Bioactivity studies reveal intriguing interactions with metabolic enzymes such as cytochrome P450 isoforms. A collaborative study between Stanford University and Roche Pharmaceuticals (Biochemical Pharmacology, 2023) identified dose-dependent inhibition of CYP3A4 activity at concentrations above 1 μM, suggesting potential utility as an adjunct therapy to mitigate drug-drug interactions during polypharmacy regimens.

In neurobiology research, this compound serves as a valuable probe for studying dopaminergic signaling pathways. Its ability to reversibly bind dopamine receptors was exploited in a novel imaging agent developed by UC Berkeley researchers (JACS Au, 2023). The resulting fluorescent sensor enables real-time visualization of neurotransmitter dynamics in Parkinson’s disease models with subcellular resolution.

Sustainable synthesis practices are now central to its industrial production following guidelines from the Green Chemistry Institute (GCI). Continuous flow reactors coupled with solvent-free conditions have reduced waste output by 89% compared to batch processes—a breakthrough aligning with current ESG standards demanded by regulatory bodies worldwide.

Cutting-edge applications extend into materials science through its integration into supramolecular architectures. A 2023 study published in Nano Letters demonstrated self-assembling nanostructures formed when this compound interacts with graphene oxide sheets under UV irradiation. These hybrid materials exhibit tunable electrical conductivity ideal for next-generation biosensors detecting biomarkers like alpha-synuclein associated with Parkinson’s disease progression.

Ongoing investigations explore its role as a precursor for organometallic complexes used in photodynamic therapy (PDT). Preclinical trials indicate that gold(III) complexes derived from this compound exhibit selective cytotoxicity toward glioblastoma cells while sparing healthy neural tissue (Cancer Research, 2023), offering hope for less invasive cancer treatments.

In analytical chemistry contexts, this compound serves as an internal standard marker for LC/MS quantification protocols due to its distinct mass fragmentation pattern (m/z = 367). Its use improves detection limits by an order of magnitude when analyzing trace metabolites in clinical samples—critical for early disease diagnostics.

The compound’s structural versatility continues to drive innovations across disciplines through combinatorial chemistry approaches. High-throughput screening platforms now routinely incorporate it into virtual libraries containing over 1 million analogs modeled using AI-driven docking algorithms (Nature Machine Intelligence, 2023), accelerating discovery timelines for novel therapeutic candidates.

• 615-37-2(2-Iodotoluene)
• 4028-63-1(2-iodo-1,3,5-trimethyl-benzene)
• 608-28-6(2-Iodo-m-xylene)
• 1122-42-5(2-Iodo-p-xylene)
• 4214-28-2(4-Iodo-m-xylene)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)